IPSEN SA SP.ADR 1/4/ EO 1 Total Liabilities
IPSEN SA SP.ADR 1/4/ EO 1 total liabilities. Based on the latest financial reports, IPSEN SA SP.ADR 1/4/ EO 1 (I7G0) has total liabilities worth €2.60 Billion EUR (≈ $3.04 Billion USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check I7G0 asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of IPSEN SA SP.ADR 1/4/ EO 1 (2021–2025)
Total liabilities of IPSEN SA SP.ADR 1/4/ EO 1 from 2021 to 2025. This chart illustrates how IPSEN SA SP.ADR 1/4/ EO 1's total liabilities have evolved over time, based on quarterly financial data.
IPSEN SA SP.ADR 1/4/ EO 1 Competitors by Total Liabilities
The table below lists competitors of IPSEN SA SP.ADR 1/4/ EO 1 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Realtek Semiconductor Corp
TW:2379
|
Taiwan | NT$96.83 Billion |
|
Acciona
MC:ANA
|
Spain | €29.57 Billion |
|
Crown Holdings Inc
NYSE:CCK
|
USA | $11.19 Billion |
|
Far EasTone Telecommunications Co Ltd
TW:4904
|
Taiwan | NT$85.18 Billion |
|
Mapfre
MC:MAP
|
Spain | €48.00 Billion |
|
Eurobank Ergasias Services and Holdings S.A.
AT:EUROB
|
Greece | €93.20 Billion |
|
Yunnan Aluminium Co Ltd
SHE:000807
|
China | CN¥11.08 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down IPSEN SA SP.ADR 1/4/ EO 1's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see total assets of IPSEN SA SP.ADR 1/4/ EO 1.
Liquidity & Leverage Metrics
IPSEN SA SP.ADR 1/4/ EO 1 Total Liabilities Ratios Explained
IPSEN SA SP.ADR 1/4/ EO 1 total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.96 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.60 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.37 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how IPSEN SA SP.ADR 1/4/ EO 1's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for IPSEN SA SP.ADR 1/4/ EO 1 (2021–2025)
The table below shows the annual total liabilities of IPSEN SA SP.ADR 1/4/ EO 1 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €2.60 Billion ≈ $3.04 Billion |
+15.23% |
| 2024-12-31 | €2.26 Billion ≈ $2.64 Billion |
-9.68% |
| 2023-12-31 | €2.50 Billion ≈ $2.92 Billion |
+10.03% |
| 2022-12-31 | €2.27 Billion ≈ $2.66 Billion |
+0.82% |
| 2021-12-31 | €2.25 Billion ≈ $2.63 Billion |
-- |
About IPSEN SA SP.ADR 1/4/ EO 1
Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience worldwide. Its oncology products include Somatuline for the treatment of neuroendocrine tumors and acromegaly; Cabometyx, a tyrosine kinase inhibitor to treat second line pancreatic and extra-pancreatic neuroendocrine tumors; Onivyde, an irinotecan liposome injec… Read more